We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Image: Visual Abstract (Seemesh Bhaskar et al., Point of care molecular cancer diagnostics, Lab on a Chip, 2026. DOI: 10.1039/d5lc01014d)

Point-of-Care Molecular Technology Promises Transformative Shift in Oncology

A new review highlights how POC molecular diagnostic technology is transforming cancer detection and treatment monitoring. More...
23 Jul 2026
Image: Workflow of 19 F NMR–based serum amino acid profiling and data analysis. Serum samples collected from CRC patients were subjected to fluorine-labeling–based amino acid detection followed by 19 F NMR spectroscopy. Quantified amino acid data were processed using ratio-based normalization and multivariate analyses to characterize stage-specific metabolic patterns and construct machine learning models for prognostic risk prediction. (Photo courtesy of KAIST)

Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis

A single preoperative blood sample may improve recurrence or metastasis prediction in colorectal cancer patients. More...
23 Jul 2026
Image: FirstGene delivers fetal chromosome, fetal single-gene, patient carrier, and fetal RhD screening in one integrated report (Photo courtesy of Myriad Genetics)

New Test Delivers Four Prenatal Genetic Screens from One Blood Sample

Myriad Genetics has launched FirstGene, a single-sample prenatal test that performs four genetic screens simultaneously. More...
22 Jul 2026
Image Credit: Adobe Stock

Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk

New findings profile gene variants and map protein defects, improving genetic test interpretation for inherited heart muscle disease. More...
22 Jul 2026
Image: The acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data, and AI platform to advance cancer monitoring, deepen insights, and accelerate growth

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal

Tempus AI has entered into a definitive agreement to acquire Personalis, expanding its capabilities in MRD testing and cancer monitoring. More...
22 Jul 2026
Image: Despite treatment advances, most multiple myeloma patients relapse and identifying high-risk cases at diagnosis remains challenging (Image Credit: Adobe Stock)

New Marker Helps Detect Aggressive Multiple Myeloma Earlier

A new study links elevated cell-adhesion protein levels to shorter survival in newly diagnosed multiple myeloma. More...
22 Jul 2026
Multiplex immunofluorescent (left) and H&E-stained (right) breast tumor samples illustrating high versus low Base Topology Scores. Higher topology scores reflect more organized tissue architecture, while lower scores indicate greater structural disorganization. By quantitatively measuring these structural differences, the researchers developed biomarkers that predicted patient outcomes more accurately than many traditional approaches. (Photo courtesy of Columbia University Irving Medical Center)

Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response

A topology-based approach quantifies tumor architecture to improve breast cancer prognosis and predict therapy response. More...
22 Jul 2026
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Automated Urinalysis Solution
UN-9000
Copyright © 2000-2026 Globetech Media. All rights reserved.